The Filing Desk

Vistagen Therapeutics

VTGN · Nasdaq · Health Care · Financials, fiscal 2017 to 2026

VTGN · Last close · November 19, 2026
$0.19
Value Vistagen Therapeutics yourself

Vistagen Therapeutics' revenue rose 161.1% to $1 million in fiscal 2026. Its operating margin was −5,683.7%, up from −11,517.1% a year earlier. The diluted share count rose 23.3%.

VISTAGEN THERAPEUTICS, INC. Latest fiscal year ended March 31, 2026 10-K filed June 15, 2026 · 0001628280-26-043271 Updated
Revenue
$1M
161.1%
Operating margin
−5,683.7%
5833.4 pts
Net income
−$70M
 
Free cash flow
—
 
Return on equity
−131.6%
75.9 pts
Market cap
$8M
Nov 19 close
P/E
—
Loss: no P/E

Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

About these figures. Share counts and per-share figures for earlier years are restated for a stock split (1-for-30.303), so every year is on today's share basis.

Charts show fiscal years, from the 10-K filings.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow

Vistagen Therapeutics lost money in fiscal 2026: a net loss of $70 million.

Diluted earnings per share
US$ per share, fiscal years, restated for any stock splits; loss years in red. Where the filings' structured data doesn't give a year's earnings per share, the column is blank.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY22FY23FY24FY25FY26
Cash and short-term investments68171198045
Debt incl. finance leases00000
Net debt (negative means net cash)−68−16−119−80−45
Net debt to EBITDA—————
Debt to equity0.0x0.0x0.0x0.0x0.0x
Interest coverage−159,263.0x———−2,185.6x
Current ratio12.3x3.8x23.6x6.5x3.7x
Quick ratio12.3x3.8x23.6x6.5x3.7x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Projections

Project Vistagen Therapeutics' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.

What Vistagen Therapeutics says to expect

  • Cash runway: into 2027Based on current operating plans, Vistagen believes its cash, cash equivalents, and marketable securities will be sufficient to fund operations into 2027 but are not expected to be sufficient to extend the Company’s cash runway for more than a year from now.
The company's own words, from its earnings release (Form 8-K, Exhibit 99), filed November 13, 2026. They are its expectations, not ours, and not a forecast or price target from The Filing Desk. Replaced when the next release is out.

Insider trades

No officer, director or 10% owner of Vistagen Therapeutics reported buying or selling its shares on the open market between November 20, 2025 and November 19, 2026.

From Form 4 filings with the SEC. Grants, option exercises and shares withheld for tax aren't counted. Insider trades at all companies

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY24FY25FY26
Piotroski F-score4 of 82 of 82 of 8
Rule of 40———
Altman Z''7.76−9.52−34.55
Accruals ratio−4.9%−9.0%−4.9%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY24FY25FY26
Net income is positiveFailFailFail
Cash from operations is positiveFailFailFail
Return on assets roseFailPassFail
Cash from operations exceeds net incomePassPassPass
Debt fell relative to assetsPassFailFail
Current ratio rosePassFailFail
Share count didn't riseFailFailFail
Gross margin rose———
Revenue rose relative to assetsPassFailPass
F-score4 of 82 of 82 of 8
Companies that report no gross profit are scored on the other eight.

Compare

Put Vistagen Therapeutics side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
Vistagen TherapeuticsFY26161.1%−5,683.7%———2
NRX PharmaceuticalsFY25—−1,324.4%————Compare
Rani TherapeuticsFY2558.9%−2,346.0%−1,151.4%−127.1%—4Compare
Dare BioscienceFY2510,429.4%−1,315.5%−997.0%———Compare
Rafael HoldingsFY26−4.7%−3,822.5%−3,431.3%———Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

10 years of figures

Fiscal yearFY17FY18FY19FY20FY21FY22FY23FY24FY25FY26
Income statement
Revenue10—011−0101
Revenue growth—−100.0%———1.8%−120.5%—−54.3%161.1%
Gross profit——————————
Research and development581713123544203955
Operating income−10−14−25−21−18−48−59−33−56−72
Net income−10−14−25−21−18−48−59−29−51−70
Diluted EPS (US$)−46.20−33.60−27.00−15.00−14.70—−8.51−1.52−1.67−1.83
Diluted shares (millions)0012377193138
Cash flow
Cash from operations−7−9−14−16−12−45−50−26−42−66
Capital expenditure00000000——
Free cash flow−8−9−15−16−12−45−50−26——
Dividends paid0000000000
Share buybacks0000000000
Acquisitions0000000000
Stock-based compensation1234243244
Balance sheet at fiscal year end
Cash and short-term investments31013110368171198045
Debt incl. finance leases0000000000
Total assets41114610875211248449
Total liabilities347121610991413
Shareholders' equity177−69265121147036
Margins and ratios
Gross margin——————————
Operating margin−819.9%———−1,646.1%−4,308.3%26,109.2%−3,103.5%−11,517.1%−5,683.7%
Net margin−820.4%———−1,646.1%−4,306.8%26,100.4%−2,759.6%−10,579.8%−5,491.3%
Free cash flow margin−600.1%———−1,133.5%−4,098.9%22,133.9%−2,426.0%——
Rule of 40 (growth + FCF margin)—————−4,097.1%22,013.5%———
Return on capital——————————
Return on equity—−380.9%−351.5%−3,087.2%−41.6%−61.0%−154.3%−46.5%−55.7%−131.6%
Return on assets−436.2%−191.4%−194.5%−210.0%−31.4%−52.2%−123.8%−40.6%−49.4%−104.9%
Net debt to EBITDA——————————
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: Vistagen Therapeutics' Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with Vistagen Therapeutics.